HIV Env-Specific IgG Antibodies Induced by Vaccination of Neonatal Rhesus Macaques Persist and Can Be Augmented by a Late Booster Immunization in Infancy.


Journal

mSphere
ISSN: 2379-5042
Titre abrégé: mSphere
Pays: United States
ID NLM: 101674533

Informations de publication

Date de publication:
25 03 2020
Historique:
entrez: 28 3 2020
pubmed: 28 3 2020
medline: 17 3 2021
Statut: epublish

Résumé

The HIV epidemics in infants and adolescent women are linked. Young women of childbearing age are at high risk for HIV infection and, due to poor HIV testing rates and low adherence to antiretroviral therapy, are at high risk for mother-to-infant transmission. We hypothesize that HIV vaccine regimens initiated in early life would provide the necessary time frame to induce mature and highly functional Env-specific antibody responses that could potentially also protect against HIV acquisition later in life. The present study was designed to test two vaccine regimens, a clade C HIV Env protein vaccine (Env only) alone or combined with a modified vaccinia Ankara (MVA) vector expressing HIV Env (MVA/Env) for the induction and persistence of Env-specific antibody responses in an infant nonhuman primate model. Vaccination was initiated within the first week of life, with booster immunizations at weeks 6, 12, and 32. We demonstrate that both vaccine strategies were able to elicit durable Env-specific antibody responses that were enhanced by a late boost in infancy. Furthermore, we confirmed earlier data that intramuscular administration of the Env protein with the Toll-like receptor 7/8 (TLR7/8)-based adjuvant 3M-052 in stable emulsion (3M-052-SE) induced higher Env-specific antibody responses than vaccination with Env adjuvanted in Span85-Tween 80-squalene (STS) tested in a previous study. These results support the concept of early vaccination as a means to induce durable immune responses that may prevent HIV infection in adolescence at the onset of sexual debut.

Identifiants

pubmed: 32213623
pii: 5/2/e00162-20
doi: 10.1128/mSphere.00162-20
pmc: PMC7096624
pii:
doi:

Substances chimiques

AIDS Vaccines 0
Adjuvants, Immunologic 0
Antibodies, Neutralizing 0
HIV Antibodies 0
HIV Envelope Protein gp120 0
Immunoglobulin G 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIH HHS
ID : K01 OD024877
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI117915
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050410
Pays : United States
Organisme : NIH HHS
ID : P51 OD011107
Pays : United States

Informations de copyright

Copyright © 2020 Curtis et al.

Références

Clin Vaccine Immunol. 2017 Oct 5;24(10):
pubmed: 28814388
Blood. 1997 Aug 1;90(3):1109-14
pubmed: 9242542
J Virol. 2019 May 1;93(10):
pubmed: 30842326
Anal Biochem. 2016 Jun 1;502:53-63
pubmed: 27019155
J Infect Dis. 2007 Oct 15;196(8):1153-62
pubmed: 17955433
Nat Commun. 2017 Jun 08;8:15711
pubmed: 28593989
J Infect Dis. 2015 Feb 15;211(4):508-17
pubmed: 25170104
Methods Mol Biol. 2009;485:395-405
pubmed: 19020839
Mucosal Immunol. 2017 Jan;10(1):228-237
pubmed: 27072605
BMJ Glob Health. 2019 Sep 20;4(5):e001363
pubmed: 31637022
J Int Assoc Provid AIDS Care. 2016 Mar-Apr;15(2):91-100
pubmed: 26715490
Swiss Med Wkly. 2017 Aug 14;147:w14465
pubmed: 28804866
Cell. 2016 Jun 30;166(1):77-87
pubmed: 27345369
J Virol. 2018 Aug 16;92(17):
pubmed: 29950423
J Virol. 2019 Feb 19;93(5):
pubmed: 30541851
Hum Vaccin Immunother. 2017 May 4;13(5):1018-1030
pubmed: 28281871
J Virol. 2018 Sep 26;92(20):
pubmed: 30089691
J Immunol Methods. 2014 Feb;404:1-12
pubmed: 24316020
J Virol. 2017 Apr 13;91(9):
pubmed: 28179536
Clin Infect Dis. 2014 Sep 15;59 Suppl 2:S80-4
pubmed: 25151483
Clin Vaccine Immunol. 2016 Jun 06;23(6):496-506
pubmed: 27098021
J Int AIDS Soc. 2017 May 16;20(Suppl 3):21520
pubmed: 28530036
World Health Stat Q. 1988;41(2):59-63
pubmed: 3176515
AIDS Res Hum Retroviruses. 2019 Mar;35(3):310-325
pubmed: 30303405
Vaccine. 2004 Jan 2;22(3-4):511-9
pubmed: 14670334
Cytometry A. 2011 Aug;79(8):603-12
pubmed: 21735545
N Engl J Med. 2009 Dec 3;361(23):2209-20
pubmed: 19843557
Curr Treat Options Infect Dis. 2015 Jun;7(2):101-112
pubmed: 25931990
Expert Opin Biol Ther. 2017 Mar;17(3):295-303
pubmed: 28095712
J Infect Dis. 2013 Apr 15;207(8):1195-205
pubmed: 22837492
Lancet Infect Dis. 2012 Jul;12(7):531-7
pubmed: 22652344
J Virol. 2017 Dec 14;92(1):
pubmed: 29021402
J Clin Invest. 2015 Jul 1;125(7):2702-6
pubmed: 26053661
J Virol. 2012 Nov;86(21):11521-32
pubmed: 22896626
Curr Opin Immunol. 2018 Aug;53:143-151
pubmed: 29775847
Vaccines (Basel). 2019 Sep 19;7(3):
pubmed: 31546894
Immunol Rev. 2013 Jul;254(1):225-44
pubmed: 23772623

Auteurs

Alan D Curtis (AD)

Department of Microbiology and Immunology, Center for AIDS Research, and Children's Research Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Maria Dennis (M)

Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.

Joshua Eudailey (J)

Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.

Korey L Walter (KL)

Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.

Kenneth Cronin (K)

Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.

S Munir Alam (SM)

Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.

Neelima Choudhary (N)

Department of Microbiology and Immunology, Center for AIDS Research, and Children's Research Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Ryan H Tuck (RH)

Department of Microbiology and Immunology, Center for AIDS Research, and Children's Research Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Michael Hudgens (M)

Department of Biostatistics, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Pamela A Kozlowski (PA)

Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.

Justin Pollara (J)

Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.

Guido Ferrari (G)

Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.
Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.

Koen K A Van Rompay (KKA)

California National Primate Research Center, University of California at Davis, Davis, California, USA.

Sallie Permar (S)

Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.

Kristina De Paris (K)

Department of Microbiology and Immunology, Center for AIDS Research, and Children's Research Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA abelk@med.unc.edu.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH